Enovis Co. (NYSE:ENOV) Given Consensus Rating of “Moderate Buy” by Analysts

Enovis Co. (NYSE:ENOV) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $67.00.

Several brokerages have recently commented on ENOV. JMP Securities began coverage on shares of Enovis in a research report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and set a $65.00 price objective on shares of Enovis in a research report on Thursday, November 7th. Finally, Evercore ISI reduced their target price on Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a report on Tuesday, October 1st.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Benjamin F. Edwards & Company Inc. raised its holdings in Enovis by 28.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock valued at $76,000 after buying an additional 371 shares during the period. Aigen Investment Management LP boosted its position in shares of Enovis by 5.1% during the third quarter. Aigen Investment Management LP now owns 8,859 shares of the company’s stock valued at $381,000 after buying an additional 430 shares during the period. FMR LLC raised its holdings in shares of Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after buying an additional 484 shares during the period. Ridgewood Investments LLC purchased a new stake in shares of Enovis in the second quarter worth approximately $44,000. Finally, State of Alaska Department of Revenue boosted its holdings in Enovis by 20.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,482 shares of the company’s stock valued at $279,000 after acquiring an additional 1,115 shares during the period. Institutional investors own 98.45% of the company’s stock.

Enovis Stock Down 1.7 %

Shares of ENOV stock opened at $46.14 on Friday. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. Enovis has a 12 month low of $38.27 and a 12 month high of $65.03. The stock has a market cap of $2.58 billion, a P/E ratio of -21.07 and a beta of 1.94. The company has a 50 day simple moving average of $44.26 and a two-hundred day simple moving average of $44.62.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $505.22 million during the quarter, compared to analysts’ expectations of $504.44 million. During the same quarter in the prior year, the business posted $0.56 earnings per share. The business’s quarterly revenue was up 21.0% on a year-over-year basis. On average, research analysts expect that Enovis will post 2.79 earnings per share for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.